Published in J Am Coll Cardiol on January 01, 1990
Is secondary mitral regurgitation in congestive heart failure a marker of clinical importance? J Am Coll Cardiol (1990) 0.96
High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. J Card Fail (2008) 0.86
Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. Br Heart J (1994) 0.77
Theodore E. Woodward Award: Coming in out of the rain. Relieving congestion in heart failure. Trans Am Clin Climatol Assoc (2009) 0.76
Biventricular pacing: impact on exercise-induced increases in mitral insufficiency in patients with chronic heart failure. Can J Cardiol (2008) 0.76
Exercise Dynamics in Secondary Mitral Regurgitation: Pathophysiology and Therapeutic Implications. Circulation (2017) 0.75
Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. Crit Care (2015) 0.75
Mitral regurgitation determined by radionuclide cardiography: dependence on posture and exercise. Br Heart J (1994) 0.75
Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med (2001) 3.39
Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med (1999) 3.20
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol (1994) 2.78
Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med (1986) 2.63
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol (1997) 2.35
The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol (2001) 2.33
Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation (1996) 2.31
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol (1992) 2.18
Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med (1991) 2.18
Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation (2009) 2.15
Informatics and medicine--from molecules to populations. Methods Inf Med (2008) 2.13
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med (2001) 2.12
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol (1990) 2.07
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol (2001) 2.00
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology (2009) 1.99
Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med (1995) 1.95
Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol (1999) 1.86
Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain (2001) 1.83
Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation (1993) 1.81
Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation (1999) 1.80
13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation (1989) 1.77
The relationship between myocardial retention of technetium-99m teboroxime and myocardial blood flow. J Am Coll Cardiol (1992) 1.68
Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol (1997) 1.68
Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med (1999) 1.63
Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med (1997) 1.61
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A (2009) 1.60
Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. J Am Coll Cardiol (1991) 1.57
Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation (1995) 1.54
A simplified method for quantification of myocardial blood flow using nitrogen-13-ammonia and dynamic PET. J Nucl Med (1993) 1.53
Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation (1984) 1.52
Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1989) 1.51
O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med (2000) 1.48
Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. J Am Coll Cardiol (1991) 1.48
Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. Eur Heart J (2001) 1.47
The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.46
Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation (1997) 1.46
A quantitative index of regional blood flow in canine myocardium derived noninvasively with N-13 ammonia and dynamic positron emission tomography. J Am Coll Cardiol (1991) 1.46
Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med (2000) 1.45
Region-specific encoding of sensory and affective components of pain in the human brain: a positron emission tomography correlation analysis. Ann Neurol (1999) 1.43
Selection of patients for cardiac evaluation before peripheral vascular operations. J Vasc Surg (1996) 1.43
Relation of myocardial perfusion at rest and during pharmacologic stress to the PET patterns of tissue viability in patients with severe left ventricular dysfunction. J Nucl Cardiol (1999) 1.42
Focal metabolic activation in the predominant left auditory cortex in patients suffering from tinnitus: a PET study with [18F]deoxyglucose. ORL J Otorhinolaryngol Relat Spec (1997) 1.42
Evidence for preserved cardiopulmonary baroreflex control of renal cortical blood flow in humans with advanced heart failure. A positron emission tomography study. Circulation (1995) 1.41
Determination of extent and location of coronary artery disease in patients without prior myocardial infarction by thallium-201 tomography with pharmacologic stress. J Nucl Med (1992) 1.41
Comparison of technetium-99m sestamibi and thallium-201 retention characteristics in canine myocardium. J Am Coll Cardiol (1992) 1.41
Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol (1994) 1.40
An automated analysis program for the evaluation of cardiac PET studies: initial results in the detection and localization of coronary artery disease using nitrogen-13-ammonia. J Nucl Med (1993) 1.39
An improved method for the quantification of left-to-right cardiac shunts. J Nucl Med (1991) 1.39
Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging (2006) 1.39
Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol (1999) 1.38
Noninvasive quantification of hepatic arterial blood flow with nitrogen-13-ammonia and dynamic positron emission tomography. J Nucl Med (1991) 1.38
Characterization of translocation contact sites involved in the import of mitochondrial proteins. J Cell Biol (1987) 1.37
Factor analysis for extraction of blood time-activity curves in dynamic FDG-PET studies. J Nucl Med (1995) 1.36
Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med (1993) 1.36
N-13 ammonia as an indicator of myocardial blood flow. Circulation (1981) 1.35
Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology (2005) 1.33
Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging (2012) 1.33
Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation (1995) 1.32
A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. Circulation (1992) 1.32
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood (1998) 1.32
Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation (1983) 1.32
Serial measurements of left ventricular ejection fraction by radionuclide angiography early and late after myocardial infarction. Am J Cardiol (1976) 1.32
Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med (1989) 1.30
Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation (1998) 1.29
Carbon-11-acetate PET imaging in renal disease. J Nucl Med (1995) 1.28
Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr (1995) 1.26
Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin (2004) 1.25
Uptake of radiolabeled 2'-fluoro-2'-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil in cardiac cells after adenoviral transfer of the herpesvirus thymidine kinase gene: the cellular basis for cardiac gene imaging. Circulation (2000) 1.22
Inter-crystal scatter in a dual layer, high resolution LSO-APD positron emission tomograph. Phys Med Biol (2003) 1.22
Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation (2000) 1.20
Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst (1996) 1.19
Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [15O]water techniques. Circulation (1996) 1.19
Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med (1997) 1.18
Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation (1994) 1.18
Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol (1991) 1.17
Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain (2001) 1.16
Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med (2001) 1.16
Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol (1990) 1.16
Vasodilator therapy for chronic left ventricular failure. Circulation (1976) 1.15
Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med (1999) 1.14
Myocardial blood flow and flow reserve after coronary reimplantation in patients after arterial switch and ross operation. Circulation (2001) 1.13